Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: A randomized clinical trial

JAMA

Volumn 310, Issue 10, 2013, Pages 1033-1041

  Mathurin, Philippe ^a,b   Louvet, Alexandre ^a,b   Duhamel, Alain ^a   Nahon, Pierre ^c   Carbonell, Nicolas ^d   Boursier, Jérôme ^e   Anty, Rodolphe ^f   Diaz, Emmanuel ^g   Thabut, Dominique ^d   Moirand, Romain ^h   Lebrec, Didier ^i,j   Moreno, Christophe ^k   Talbodec, Nathalie ^l   Paupard, Thierry ^m   Naveau, Sylvie ⁿ   Silvain, Christine ^o   Pageaux, Georges Philippe ^p   Sobesky, Rodolphe ^q   Canva Delcambre, Valérie ^a   Dharancy, Sébastien ^a,b   Salleron, Julia ^a   Dao, Thong ^r   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c HÔPITAL JEAN VERDIER   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g centre hospitalier de Béthune   (France)

^h PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁱ CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^j BEAUJON HOSPITAL   (France)

^k ERASME HOSPITAL   (Belgium)

^l Service d'Hépato Gastroentérologie   (France)

^m service des urgences   (France)

ⁿ HÔPITAL ANTOINE BÉCLÈRE   (France)

^o POITIERS UNIVERSITY HOSPITAL   (France)

^p HÔPITAL SAINT ELOI   (France)

^q HÔPITAL PAUL BROUSSE   (France)

^r CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PLACEBO; PREDNISOLONE;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEPATORENAL SYNDROME; HUMAN; HUMAN TISSUE; INCIDENCE; INFECTION; JAUNDICE; LILLE MODEL; MADDREY DISCRIMINANT FUNCTION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT TERM SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 84883734359     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.276300     Document Type: Article

References (27)

1. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141(5):1572-1585.
2. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758-2769.
3. Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003;38(6):1363-1369. (Pubitemid 37466961)
4. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med. 1989;110(9):685-690. (Pubitemid 19121221)
5. Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36(4):480-487. (Pubitemid 34407335)
6. Naveau S, Chollet-Martin S, Dharancy S, et al; Foie-Alcool group of the Association Française pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39(5):1390-1397. (Pubitemid 38569061)
7. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(6):1637-1648. (Pubitemid 32198689)
8. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15(13):1613-1619.
9. Sidhu SS, Goyal O, Singla P, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci. 2012;57(6):1664-1671.
10. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57(2):399-420.
11. O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010;51(1):307-328.
12. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990;172(1):391-394. (Pubitemid 20217287)
13. Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4(1):24-34. (Pubitemid 46055957)
14. Taïeb J, Mathurin P, Elbim C, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol. 2000;32(4):579-586. (Pubitemid 30180377)
15. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348-1354. (Pubitemid 46918318)
16. Louvet A, Wartel F, Castel H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009;137(2):541-548.
17. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193-199. (Pubitemid 8372264)
18. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41(2):353-358. (Pubitemid 40165379)
19. Wiesner R, Edwards E, Freeman R, et al United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91-96. (Pubitemid 36055342)
20. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-1318. (Pubitemid 47300435)
21. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer Verlag; 2000.
22. Marshall A, Altman DG, Royston P, Holder RL. Comparison of techniques for handlingmissing covariate data within prognostic modelling studies: a simulation study. BMC Med Res Methodol. 2010;10:7.
23. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
24. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790-1800.
25. Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60(2):255-260.
26. Richardet J, Dehoux M, Mal F, et al. Influence of corticosteroids on plasma cytokines concentrations in patients with severe alcoholic hepatitis [abstract]. J Hepatol. 1993;18:S75.
27. Lebrec D, Thabut D, Oberti F, et al Pentocir Group. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology. 2010;138(5):1755-1762.